0000000000586965

AUTHOR

Ml Scribano

showing 3 related works from this author

Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study

2016

Background and Aims: Cancer risk in inflammatory bowel disease [IBD] is still debated. In a prospective, multicentre, nested case-control study, we aimed to characterise incident cases of cancer in IBD. The role of immunomodulators vs clinical characteristics of IBD as risk factors for cancer was also investigated. Materials and Methods: From January 2012 to December 2014, each IBD patient with incident cancer was matched with two IBD patients without cancer for: IBD type, gender, and age. Risk factors were assessed by multivariate regression analysis. Results: IBD patients considered numbered 44619: 21953 Crohn’s disease \[CD], 22666 ulcerative colitis [UC]. Cancer occurred in 174 patients…

AdultMalemedicine.medical_specialtyPancolitisAdolescentColorectal cancerphenotypeSettore MED/12 - GASTROENTEROLOGIAcancer riskInflammatory bowel disease; cancer risk; phenotype; Adolescent; Adult; Aged; Aged 80 and over; Case-Control Studies; Female; Follow-Up Studies; Humans; Immunologic Factors; Incidence; Inflammatory Bowel Diseases; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neoplasms; Prospective Studies; Risk Factors; Young Adult; PhenotypeGastroenterologyInflammatory bowel diseaseInflammatory bowel disease03 medical and health sciencesYoung Adult0302 clinical medicineRisk FactorsInternal medicineNeoplasms80 and overmedicineHumansImmunologic FactorsProspective StudiesRisk factorProspective cohort studyAgedAged 80 and overbusiness.industryIncidenceSettore MED/09 - MEDICINA INTERNAGastroenterologyCancerGeneral MedicineMiddle Agedmedicine.diseaseInflammatory Bowel DiseasesUlcerative colitisLogistic Models030220 oncology & carcinogenesisCase-Control StudiesNested case-control studyMultivariate Analysis030211 gastroenterology & hepatologyFemalemedicine.symptombusinessInflammatory bowel disease; cancer risk; phenotypeFollow-Up Studies
researchProduct

Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy.

2022

Abstract Background Adalimumab is used to treat ulcerative colitis, but additional effectiveness and safety data are needed. Patients and methods This retrospective study considered adults with ulcerative colitis treated with adalimumab at 19 hospitals. Clinical data were collected from the start of treatment, after 2, 6 and 12 months, and at the last visit. Outcome measures of effectiveness were treatment duration, reasons for discontinuation and colectomy. Results We studied 381 patients treated with adalimumab for a median of 12.1 months. Disease activity at the start of treatment was moderate to severe in 262 cases (68.8%) and endoscopic activity was moderate to severe in 339 cases (89.…

musculoskeletal diseasesAdultMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentEffectivenessYoung AdultInternal medicineAdalimumabMedicineHumansAdverse effectskin and connective tissue diseasesColectomyColectomyAgedRetrospective StudiesReal-world evidenceHepatologybusiness.industryGastroenterologyEffectiveneAdalimumabRetrospective cohort studyInduction ChemotherapyMiddle Agedmedicine.diseaseUlcerative colitisDiscontinuationClinical PracticeTreatment OutcomeUlcerative colitisItalyAdalimumab; Effectiveness; Real-world evidence; Safety; Ulcerative colitisConcomitantColitis UlcerativeFemaleTumor Necrosis Factor InhibitorsSafetybusinessmedicine.drugDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin.

2006

1. Aliment Pharmacol Ther. 2006 Apr 15;23(8):1117-25. Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Prantera C, Lochs H, Campieri M, Scribano ML, Sturniolo GC, Castiglione F, Cottone M. Operative Unit of Gastroenterology, St Camillo-Forlanini Hospital, Rome, Italy. prantera@tin.it BACKGROUND: Clinicians often employ antibiotics in Crohn's disease. Rifaximin is active against bacteria frequently found in the intestinal mucosa of Crohn's disease patients. AIM: To evaluate the difference in efficacy between once and twice/daily oral administration of rifaximin and placebo in the treatment of active Crohn's …

AdultMalemedicine.medical_specialtyPlacebo-controlled studyCIPROFLOXACINPlaceboGastroenterologyInflammatory bowel diseaseDrug Administration ScheduleRifaximinPlaceboschemistry.chemical_compoundCrohn DiseaseDouble-Blind MethodIntestinal mucosaINFLAMMATORY-BOWEL-DISEASE C-REACTIVE PROTEIN ULCERATIVE-COLITIS METRONIDAZOLE CIPROFLOXACIN MANAGEMENT RECURRENCE DIARRHEA ANTIBODY MODERATEInternal medicinemedicineMANAGEMENTHumansPharmacology (medical)RECURRENCEAntibacterial agentCrohn's diseaseChi-Square DistributionHepatologybusiness.industryGastroenterologyMiddle Agedmedicine.diseaseRifamycinsUlcerative colitisDIARRHEAC-REACTIVE PROTEINAnti-Bacterial AgentsSurgeryRifaximinTreatment OutcomechemistryULCERATIVE-COLITISANTIBODYMETRONIDAZOLEAcute Diseaserifaximin.crohn's diseaseMODERATEFemalebusinessINFLAMMATORY-BOWEL-DISEASE
researchProduct